Bromfenac: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Ophthalmic
Postoperative ocular inflammation

Adult: As 0.07% or 0.09% soln: Instill 1 drop in the affected eye(s) once daily, starting 1 day before, and continuing until 14 days after cataract surgery. Alternatively (as 0.09% soln), 1 drop bid, beginning 24 hr after cataract surgery and continuing through the 1st 14 days of post-op period.

Contraindications

Hypersensitivity to bromfenac or other NSAIDs. Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or by other medicinal products w/ prostaglandin synthetase inhibiting activity.

Special Precautions

Patient w/ complicated ocular surgeries, corneal denervation, corneal epithelial defects, DM, ocular surface diseases (e.g. dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries w/in a short period of time. Patient w/ a predisposition to bleeding (bleeding tendencies or medications which interfere w/ coagulation). Pregnancy and lactation.

Adverse Reactions

Abnormal ocular sensation, conjunctival hyperaemia, ocular redness or irritation (e.g. pruritus, burning, stinging, pain), headache and iritis.

Pregnancy Category (US FDA)

Ophth: C

Patient Counseling Information

Do not wear contact lens during treatment. This drug may cause transient blurring of vision, if affected, do not drive or operate machinery.

Drug Interactions

Increased potential for healing problems w/ concomitant ophth corticosteroids.

Action

Description: Bromfenac has anti-inflammatory activity due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2.
Pharmacokinetics:
Absorption: Efficiently permeates the cornea of cataract patients.
Distribution: Plasma protein binding: 99.8%.
Metabolism: Mainly metabolised by CYP2C9 isoenzyme in the liver.
Excretion: Half-life: 1.4 hr (aqueous humour).

Chemical Structure

Storage

Store between 15-25ºC.

MIMS Class

Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories

ATC Classification

S01BC11 - bromfenac ; Belongs to the class of non-steroidal antiinflammatory agents. Used in the treatment of inflammation of the eye.

References

Anon. Bromfenac. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/03/2016.

Bromday Solution/Drops (Ista Pharmaceuticals, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/03/2016.

Buckingham R (ed). Bromfenac Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Bromfenac Sodium (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/03/2016.

Disclaimer: This information is independently developed by MIMS based on Bromfenac from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com